Max Davidson
Research Subjects
Research Interests
Max Davidson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anders Karlsson
Nanoxis AB, Lennart Torstenssonsgatan 5, SE-40016, Gothenburg, Sweden
1 shared publication - Carl Hay
MedImmune, One MedImmune Way, Gaithersburg, MD, 20287, USA.
1 shared publication - David Lowne
MedImmune, Granta Park, Cambridge, CB21 6GH, UK
1 shared publication - Erin Brand
MedImmune, One MedImmune Way, Gaithersburg, MD, 20287, US
1 shared publication - Gene Kurosawa
Division of Biological Sciences, Graduate School of Science, Nagoya University, Nagoya, Aichi 460-8602, Japan
1 shared publication - John G. Elvin
MedImmune, Granta Park, Cambridge, CB21 6GH, UK
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 11
Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type
The continued discovery of therapeutic antibodies, which address unmet medical needs, requires the continued discovery of tractable antibody targets. Multiple protein-level target discovery approaches are available and these can be used in combination to extensively survey relevant cell membranomes. In this study, the MDA-MB-231 cell line was selected for membranome survey as it is a ‘triple negative’ breast cancer cell line, which represents a cancer subtype that is aggressive and has few treatment options.
- 1 January 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 11
Open AccessCombining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type
The continued discovery of therapeutic antibodies, which address unmet medical needs, requires the continued discovery of tractable antibody targets. Multiple protein-level target discovery approaches are available and these can be used in combination to extensively survey relevant cell membranomes. In this study, the MDA-MB-231 cell line was selected for membranome survey as it is a ‘triple negative’ breast cancer cell line, which represents a cancer subtype that is aggressive and has few treatment options.